Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

24.40 -0.16 (-0.65%)

Streaming Delayed Price Updated: 10:25 AM EST, Dec 16, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	218,765
Open	24.49
Bid (Size)	24.37 (100)
Ask (Size)	24.41 (300)
Prev. Close	24.56
Today's Range	24.31 - 24.88
52wk Range	16.10 - 35.70
Shares Outstanding	116,457,008
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Arteris Fortifies AI-Driven Future with Strategic Acquisition of Cycuity, Championing Semiconductor Cybersecurity

December 11, 2025

SAN JOSE, CA – December 11, 2025 – In a pivotal move poised to redefine the landscape of semiconductor design and cybersecurity, Arteris, Inc. (NASDAQ: APLS), a leading provider of system IP for...

Via TokenRing AI

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Emerges as a Prime GARP Investment ↗

December 06, 2025

Apellis Pharmaceuticals exemplifies the GARP strategy with strong commercial growth, recent profitability, and a valuation attractive relative to biotech peers.

Via Chartmill

Performance

YTD	-26.4%	-26.4%
1 Month	+21.4%	+21.4%
3 Month	+0.0%	+0.0%
6 Month	+33.3%	+33.3%
1 Year	-27.5%	-27.5%

More News

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

December 03, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary ↗

August 18, 2025

Via Stocktwits

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

November 25, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Presents an Affordable Growth Opportunity ↗

November 13, 2025

Via Chartmill

This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power ↗

November 12, 2025

Via Benzinga

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

November 12, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 06, 2025

Via Benzinga

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

November 05, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

These stocks are moving in today's session ↗

October 30, 2025

Via Chartmill

Here are the top movers in Thursday's session. ↗

October 30, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 30, 2025

Via Benzinga

The market is filled with gapping stocks in Thursday's session. ↗

October 30, 2025

Via Chartmill

Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reports Strong Q3 2025 Earnings Beat ↗

October 30, 2025

Via Chartmill

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

October 30, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Insights Ahead: Apellis Pharmaceuticals's Quarterly Earnings ↗

October 29, 2025

Via Benzinga

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

October 20, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

October 16, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 11 Analysts ↗

October 15, 2025

Via Benzinga

12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know ↗

September 26, 2025

Via Benzinga

Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

September 26, 2025

Via Benzinga

Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket ↗

September 26, 2025

Via Benzinga

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

August 27, 2025

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Apellis Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Apellis Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Apellis Pharmaceuticals, Inc. - Common Stock trade on?

Apellis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Apellis Pharmaceuticals, Inc. - Common Stock is APLS on the Nasdaq Stock Market

What is the current price of Apellis Pharmaceuticals, Inc. - Common Stock?

The current price of Apellis Pharmaceuticals, Inc. - Common Stock is 24.40

When was Apellis Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Apellis Pharmaceuticals, Inc. - Common Stock was at 12/16/25 10:25 AM ET

What is the market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Apellis Pharmaceuticals, Inc. - Common Stock is 2.84B

How many shares of Apellis Pharmaceuticals, Inc. - Common Stock are outstanding?

Apellis Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.